LncRNA-ATB promotes trastuzumab resistance and invasionmetastasis cascade in breast cancer

Oncotarget

Volumn 6, Issue 13, 2015, Pages 11652-11663

  Shi, Sheng Jia ^a   Wang, Li Juan ^b   Yu, Bo ^a   Li, Yun Hui ^a   Jin, Yong ^a   Bai, Xiao Zhong ^a  

^a No 202 Hospital of PLA   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Breast cancer; EMT; Lnc ATB; TGF ; Trastuzumab resistance

Indexed keywords

LONG UNTRANSLATED RNA; MICRORNA 200C; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZNF 217 PROTEIN; ANTINEOPLASTIC AGENT; HOMEODOMAIN PROTEIN; MICRORNA; MIRN200 MICRORNA, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN; ZNF217 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST METASTASIS; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PHENOTYPE; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN RNA BINDING; SIGNAL TRANSDUCTION; SKBR 3 CELL LINE; TUMOR INVASION; TUMOR PROMOTION; UPREGULATION; WILD TYPE; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TIME FACTOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; PHENOTYPE; RNA INTERFERENCE; RNA, LONG NONCODING; SIGNAL TRANSDUCTION; TIME FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UP-REGULATION; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84929630737     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3457     Document Type: Article

References (34)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014;64:9-29.
2. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Advances in experimental medicine and biology. 2007;608:1-22.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
4. Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Frontiers in oncology. 2012;2:62.
5. Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, Wolmark N. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. Journal of the National Cancer Institute. 2000;92:1991-1998.
6. Gajria D, Chandarlapaty S. HER2-amplified breast cancer:mechanisms of trastuzumab resistance and novel targeted therapies. Expert review of anticancer therapy. 2011;11:263-275.
7. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, Sahin AA, Esteva FJ, Hortobagyi GN, Yu D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature medicine. 2011;17:461-469.
8. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002;20:1800-1808.
9. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast cancer research : BCR. 2006;8:215.
10. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of clinical oncology:official journal of the American Society of Clinical Oncology. 2007;25:118-145.
11. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer research. 2009;69:2191-2194.
12. Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L, Farci P, Mishra L. Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma. Nature reviews Gastroenterology & hepatology. 2012;9:530-538.
13. Massague J. TGFbeta in Cancer. Cell. 2008;134:215-230.
14. Sabe H. Cancer early dissemination: cancerous epithelialmesenchymal transdifferentiation and transforming growth factor beta signalling. Journal of biochemistry. 2011;149:633-639.
15. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nature reviews Drug discovery. 2012;11:790-811.
16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
17. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature reviews Cancer. 2009;9:265-273.
18. Wang SE. The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-beta Signaling in Breast Cancer Malignancy. Journal of signal transduction. 2011;2011:804236.
19. Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. The American journal of pathology. 2009;174:1588-1593.
20. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629-641.
21. Sun YW, Chen YF, Li J, Huo YM, Liu DJ, Hua R, Zhang JF, Liu W, Yang JY, Fu XL, Yan T, Hong J, Cao H. A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1alpha in pancreatic ductal adenocarcinoma. British journal of cancer. 2014;111:2131-2141.
22. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W, Wang TT, Zhou CC, Wang SB, Wang YZ, Yang Y, Yang N, Zhou WP, Yang GS, et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer cell. 2014;25:666-681.
23. Meng J, Li P, Zhang Q, Yang Z, Fu S. A four-long noncoding RNA signature in predicting breast cancer survival. Journal of experimental & clinical cancer research: CR. 2014;33:84.
24. Su X, Malouf GG, Chen Y, Zhang J, Yao H, Valero V, Weinstein JN, Spano JP, Meric-Bernstam F, Khayat D, Esteva FJ. Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget. 2014;5:9864-9876.
25. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H, Song E. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. The Journal of biological chemistry. 2011;286:19127-19137.
26. Bai WD, Ye XM, Zhang MY, Zhu HY, Xi WJ, Huang X, Zhao J, Gu B, Zheng GX, Yang AG, Jia LT. MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. International journal of cancer Journal international du cancer. 2014;135:1356-1368.
27. Garcia AG, Nedev H, Bijian K, Su J, Alaoui-Jamali MA, Saragovi HU. Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs. Oncogene. 2013;32:2527-2533.
28. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30:593-599.
29. Vendrell JA, Thollet A, Nguyen NT, Ghayad SE, Vinot S, Bieche I, Grisard E, Josserand V, Coll JL, Roux P, Corbo L, Treilleux I, Rimokh R, Cohen PA. ZNF217 is a marker of poor prognosis in breast cancer that drives epithelialmesenchymal transition and invasion. Cancer research. 2012;72:3593-3606.
30. Hilmarsdottir B, Briem E, Bergthorsson JT, Magnusson MK, Gudjonsson T. Functional Role of the microRNA-200 Family in Breast Morphogenesis and Neoplasia. Genes. 2014;5:804-820.
31. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO reports. 2008;9:582-589.
32. Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. The Journal of biological chemistry. 2004;279:24505-24513.
33. Seton-Rogers SE, Lu Y, Hines LM, Koundinya M, LaBaer J, Muthuswamy SK, Brugge JS. Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:1257-1262.
34. Joshi JP, Brown NE, Griner SE, Nahta R. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. Biochemical pharmacology. 2011;82:1090-1099.